The capacity of dissolution of active component of the tablet of ciproflaxacin. 6 samples composing of 78 domestic and foreign ciprofloxacin tablet were tested. Results showed that 2 of 3 samples of domestic tablet did not meet the requirement for dissolution mentioned to USP XXIII, while the foreign tablets manifested a rate of dissolution higher than that of pharmacopea
Ciprofloxacin ; Pharmaceutical Preparations ; Tablets

No abstract available.
Ciprofloxacin* ; Mycobacterium tuberculosis* ; Mycobacterium*

No abstract available.
Ciprofloxacin* ; Vibrio vulnificus* ; Vibrio*

No abstract available.
Chromatography, Liquid* ; Ciprofloxacin* ; Therapeutic Equivalency*

No abstract available.
Ciprofloxacin* ; Enoxacin* ; Humans* ; Metabolism* ; Theophylline*

This study was conducted to determine the safe intravitreal dosage of ciprofloxacin. Twenty-four phakic eyes of New Zealand pigmented rabbits were used. Each group(4 eyes) received midvitreal ciprofloxacin of 100, 200, 400, 600, 800 micro gram in 0.1ml BSS Plus, or 0.1ml BSS Plus only as control. We evaluated retinal function by measuring the electroretinograms for a graded series of flash intensities and fitting b-wave amplitudes to the Naka-Rushton equation. At a dose of greater than 600 micro gram, Rmax decreased signifantly and log K increased signifantly. N-value decreased slightly. B-wave amplitude decreased as a toxic response of intravitreal ciprofloxacin in a dose dependent manner, and this response was best detected using lower luminance stimuli. Lower luminance electroretinography revealed a significant decrease in b-wave amplitude in eyes injected with a dose of 400 micro gram or more. We concluded that 200 micro gram will be the safe intravitreal dosage of ciprofloxacin in phakic rabbit eyes.
Ciprofloxacin* ; Electroretinography* ; New Zealand ; Rabbits ; Retinaldehyde

BACKGROUND/AIMS: Ciprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea. METHODS: We performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure. RESULTS: Intent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67% vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups. CONCLUSIONS: These results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea.
Ciprofloxacin ; Diarrhea ; Humans ; Korea ; Rifamycins ; Treatment Failure

To investigate the therapeutic effect of ciprofloxacin for the treatment of endophthalmitis, we used 18 rabbits with Staphylococcus aureus induce dendophthalmitis. The rabbits were assigned into three groups according to the treatment regimen; those who were not given any drug into group I, those who were given 100 microgram/ml ciprofloxacin intrvitreally into group II, and those who were given 2 mg/ml ciprofloxacin subconjunctivaly for 5 days into group III. We assessed clinical score, culture result of vitreous aspirate and pathologic finding of various ocular tissue. We found clinically significant decrease in clinical score in group II, but there were no significant differences in the vitreous culture and in the histologic findings among the study groups. In conclusion, we assume that intravitreal injection of ciprofloxacin may be the better treatment modality to treat endophthalmitis by S.aureus. In addition we still think there ought to be more studies as to the determination the dosage of ciprofloxacin and the use of steroid in combination.
Ciprofloxacin ; Endophthalmitis* ; Intravitreal Injections ; Rabbits ; Staphylococcus aureus

No abstract available.
Ciprofloxacin* ; Methicillin Resistance* ; Methicillin-Resistant Staphylococcus aureus*

Aims: Typhoid fever is a life-threatening disease in the developing world that claims >600,000 deaths per year. Its causative agent Salmonella Typhimurium (S. Typhi) can be treated with ciprofloxacin, an effective broad-spectrum antibiotic that enhances the natural host defenses. However, the emergence of resistant bacterial strains may be a warning alarm against the clinical use of this antibiotic. This study was aimed to investigate the efficiency of ciprofloxacin treatment (250 mg/mL) against S. Typhi by altering the production of serum cytokines IL-10, 1L-6 and TNF-α in acute typhoid fever patients in Diwanyah Hospitals. Methodology and results: ELISA and Western Blot methods were used to investigate cytokine levels in patients and healthy controls sera. Our results showed that all cytokines’ levels before treatment with ciprofloxacin were significantly higher than the control (healthy group). However, treated patients with ciprofloxacin revealed a significantly reduced concentration of IL-10 and TNF-α compared to untreated control samples. However, the level of IL-6 was higher even with ciprofloxacin treatment. Conclusion, significance and impact of study The study concluded that ciprofloxacin (250 mg/mL) might significantly alter serum cytokines IL-6, IL-10 and TNF-α levels in acute typhoid fever patients. Therefore, further molecular studies are essential to understand the effect of ciprofloxacin on the production of cytokines.
Typhoid Fever ; Ciprofloxacin ; Salmonella typhimurium ; Cytokines